Phio Pharmaceuticals Corp. (PHIO)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$10.8M
Cash & Equivalents
$4.0M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$12M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-31 Phase1 Readout —

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06014086 Intratumoral PH-762 for Cutaneous Carcinoma PHASE1 Active Not Recruiting 30
NCT05902520 Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors PHASE1 Active Not Recruiting 18

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for PHIO.

SEC EDGAR Filings

All SEC filings for Phio Pharmaceuticals Corp. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.